You just read:

Biohaven Enrolls First Patient in Pivotal Phase 3 Clinical Trial of Oral Rimegepant for the Acute Treatment of Migraine

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Jul 24, 2017, 03:00 ET